Peter JH Scott, PhD

 Peter J. Scott
Paul L Carson Ph.D. Legacy Professor of Radiology
Associate Chair, Basic Science Research
Program Assistant, Cyclotron Facility, Department of Radiology
Professor of Pharmacology, Medical School
Professor of Medicinal Chemistry, College of Pharmacy
[email protected]
Available to mentor
Peter JH Scott, PhD
Peter J. Scott
Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • Qualifications
    • PhD
      University of Durham, Durham, United Kingdom
      2001 - 2005
    • BSc
      Loughborough University, Loughborough, Leicestershire,, United Kingdom
      1997 - 2001

    Center Memberships
    • Center Member
      Biosciences Initiative
    • Center Member
      Rogel Cancer Center

    Research Overview

    - Developing new methods for radiolabeling bioactive molecules.
    - Design and synthesis of new radiotracers for PET imaging of CNS disorders such as Alzheimer's disease.
    - cGMP radiopharmaceutical manufacture.
    - Implementation of new technology for radiochemistry and PET imaging, including automation, artificial intelligence and the internet of things.
    .

    Recent Publications

     See All Publications
    • Journal Article
      Highlight selection of radiochemistry and radiopharmacy developments by editorial board
      Kiss OC, Penuelas I, Rey A, Yang Z, Gillings N, Pillai A, Cazzola E, Reilly RM, Taddei C, Liu J, van Dam M, Furumoto S, Zhang J, Bernardes ES, Lodi F, Deuther-Conrad W, Huang YY, Lagebo YJ, Ekoume FP, Avila-Rodriguez MA, Summers B, Elrefaei A, Salgueiro M, Ramogida CF, Scott PJH. Ejnmmi Radiopharmacy and Chemistry, 2026 Dec 1; 11 (1): DOI:10.1186/s41181-026-00443-1
    • Journal Article
      Functionalization of indoles using a DABCO-Meldrum's acid reagent
      Allen AC, Kim H, Hubers D, Kim I, Han G, Scott PJH, Witek JA. Tetrahedron Letters, 2026 Sep 1; 182: DOI:10.1016/j.tetlet.2026.156154
    • Journal Article
      Imaging Primary Chronic Pain Syndromes: Current Evidence, Clinical Relevance, and Advances in MRI and PET/CT
      Ora M, Cai Y, Bathla G, Agarwal A, Gupta V, Scott PJH, Soni N. Seminars in Roentgenology, 2026 Jul 1; 63: DOI:10.1016/j.ro.2026.151004
    • Journal Article
      Topography of Regional Cerebral GABAA Receptor Availability in Parkinson's Disease Patients With Freezing of Gait
      Hart AA, Kanel P, Barr J, Carli G, Vangel R, Michalakis F, Scott PJH, Roytman S, Bohnen NI. European Journal of Neuroscience, 2026 Jul 1; 64 (1): DOI:10.1111/ejn.70618
    • Preprint
      Assessment of PET Drug Adverse Events in the U.S. since the Implementation of 21 CFR part 212
      Dakanali M, VanBrocklin HF, Zigler SS, Scott PJH. 2026 Jun 11; Research Square, DOI:10.21203/rs.3.rs-9826575/v1
    • Journal Article
      Industry-Academic Collaboration in Nuclear Medicine: Proceedings from the 2024 CMIIT Industry Partners Circle.
      Osborne D, Cutler CS, Chaple IF, Ribeiro Pereira PM, Peterson TE, Solingapuram Sai KK, Wang J, Scott PJH, Chen DL. J Nucl Med, 2026 May 28; DOI:10.2967/jnumed.126.272619
      PMID: 42209122
    • Journal Article
      Illuminating proinflammatory myeloid cells with PET tracers targeting GPR84
      Kalita M, Kuo RC, Straniero V, Reyes ST, Pandrala M, Lanzini A, Marsango S, D’Moore D, Mahn P, Setiadi A, Sundar M, Mak S, Nagy S, Alam IS, Jain P, Inay G, Malek R, Brooks AF, Beinat C, Valoti E, Scott PJH, Milligan G, James ML. Proceedings of the National Academy of Sciences of the United States of America, 2026 May 26; 123 (21): DOI:10.1073/pnas.2536372123
      PMID: 42166242
    • Journal Article
      Kappa opioid receptor availability correlates with depressive symptom burden in chronic migraine: a preliminary investigation.
      Kim DJ, Saberi M, Kaur T, Shao X, Koeppe RA, Scott PJH, Porreca F, DaSilva AF. J Headache Pain, 2026 May 25; DOI:10.1186/s10194-026-02398-9
      PMID: 42185954

    Featured News & Stories
    Department News

    Atonco and University of Michigan Announce Collaboration on Phase 1-2a Clinical Study of ATO-101™

    Bladder cancer ranks among the most common cancers, with limited success from current therapies like BCG. Atonco’s ATO-101™, a targeted radiopharmaceutical using astatine-211, will be tested in a Phase 1–2a trial led by Drs. Viglianti and Scott to assess its precision and safety. This study represents a promising step toward more effective, less invasive treatments for bladder cancer.
    Department News

    Faculty Promotions (effective September 1, 2023)

    Faculty Promotions (effective September 1, 2023) at the U-M Medical School Department of Pharmacology